NASDAQ:CGIX - Cancer Genetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.86 -0.02 (-2.27 %)
(As of 07/17/2018 05:33 AM ET)
Previous Close$0.88
Today's Range$0.86 - $0.95
52-Week Range$0.82 - $4.00
Volume50,100 shs
Average Volume67,493 shs
Market Capitalization$24.32 million
P/E RatioN/A
Dividend YieldN/A
Cancer Genetics logoCancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

Receive CGIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories


Debt-to-Equity Ratio0.03
Current Ratio0.92
Quick Ratio0.92


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$29.12 million
Price / Sales0.82
Cash FlowN/A
Price / CashN/A
Book Value$0.97 per share
Price / Book0.89


EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,880,000.00
Net Margins-52.87%
Return on Equity-77.26%
Return on Assets-38.54%


Outstanding Shares27,750,000
Market Cap$24.32

The Truth About Cryptocurrencies

Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics Inc (NASDAQ:CGIX) announced its quarterly earnings results on Tuesday, May, 15th. The medical research company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.03. The medical research company earned $7.67 million during the quarter, compared to the consensus estimate of $10.20 million. Cancer Genetics had a negative net margin of 52.87% and a negative return on equity of 77.26%. View Cancer Genetics' Earnings History.

What price target have analysts set for CGIX?

3 Wall Street analysts have issued 12-month target prices for Cancer Genetics' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $4.50 in the next year. This suggests a possible upside of 423.3% from the stock's current price. View Analyst Ratings for Cancer Genetics.

What is the consensus analysts' recommendation for Cancer Genetics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cancer Genetics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Cancer Genetics stock?

Here are some recent quotes from research analysts about Cancer Genetics stock:
  • 1. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (7/3/2018)
  • 2. Maxim Group analysts commented, "We are downgrading CGIX to Hold, from Buy and removing our price target following disappointing 4Q revenues, an increase in bad debt expense which was a surprise that leaves us with some concerns around the company’s ability to collect account receivables related to acquired testing platforms and/ or companies, and in our view, a lack of strategic direction of the company. 4Q17 revenue of $7.5M, up 4% y/y compared to the consensus estimate of $9.2M. Operating expenses in 4Q17 rose 82% and included $4.4M in bad debt expense." (4/3/2018)

Who are some of Cancer Genetics' key competitors?

Some companies that are related to Cancer Genetics include Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Biocept (BIOC), OpGen (OPGN) and CBA Florida (CBAI).

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the folowing people:
  • Mr. John A. Roberts, Interim CEO & COO (Age 59)
  • Dr. Raju S. K. Chaganti, Founder & Director (Age 85)
  • Mr. Igor Gitelman CPA, MBA, Chief Accounting Officer (Age 42)
  • Mr. Cory Hickmon, VP of Bus. Devel. and Director of National Clinical Sales
  • Ms. Molly Lukes PHR, SHRM-CP, VP of HR

Has Cancer Genetics been receiving favorable news coverage?

News headlines about CGIX stock have trended somewhat negative this week, Accern reports. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cancer Genetics earned a news impact score of -0.04 on Accern's scale. They also assigned media stories about the medical research company an impact score of 43.63 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Cancer Genetics?

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $0.86.

How big of a company is Cancer Genetics?

Cancer Genetics has a market capitalization of $24.32 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]

MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.